# Combination Assessment Trial of COVID-19 Vaccines (COMBAT-COVID)

> **NCT05162482** · PHASE2 · UNKNOWN · sponsor: **Aga Khan University Hospital, Pakistan** · enrollment: 1680 (estimated)

## Conditions studied

- COVID 19 Vaccine

## Interventions

- **BIOLOGICAL:** BIBP (CNBG, Sinopharm) WIV
- **BIOLOGICAL:** CanSinoBIO
- **BIOLOGICAL:** AstraZeneca ChAdOx

## Key facts

- **NCT ID:** NCT05162482
- **Lead sponsor:** Aga Khan University Hospital, Pakistan
- **Sponsor class:** OTHER
- **Phase:** PHASE2
- **Study type:** INTERVENTIONAL
- **Status:** UNKNOWN
- **Start date:** 2022-03-01
- **Primary completion:** 2024-06-30
- **Final completion:** 2024-06-30
- **Target enrollment:** 1680 (ESTIMATED)
- **Last updated:** 2022-02-18

## Collaborators

- [object Object]
- [object Object]
- [object Object]
- [object Object]
- [object Object]
- [object Object]

## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT05162482

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT05162482, "Combination Assessment Trial of COVID-19 Vaccines (COMBAT-COVID)". Retrieved via AI Analytics 2026-06-25 from https://api.ai-analytics.org/clinical/NCT05162482. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*